Syndax Announces Participation in November Investor Conferences

Rhea-AI Summary

Syndax (Nasdaq: SNDX) announced management will participate in multiple investor conferences in November 2025, featuring fireside chats by CEO Michael A. Metzger and other executives.

Scheduled appearances: UBS Global Healthcare Conference on Nov 10, 2025 at 11:00 a.m. ET; Guggenheim Healthcare Innovation on Nov 11, 2025 at 3:00 p.m. ET; Stifel Healthcare Conference on Nov 13, 2025 at 10:00 a.m. ET; and Jefferies London Healthcare Conference on Nov 20, 2025 at 10:00 a.m. GMT / 5:00 a.m. ET.

A live webcast and limited-time replay will be available in the Investor section at www.syndax.com.

NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, as well as members of the Syndax management team, will participate in the following upcoming investor conferences:

• UBS Global Healthcare Conference 2025 with a fireside chat on Monday, November 10, 2025, at 11:00 a.m. ET.  
• Guggenheim Second Annual Healthcare Innovation Conference with a fireside chat on Tuesday, November 11, 2025, at 3:00 p.m. ET.
• Stifel 2025 Healthcare Conference with a fireside chat on Thursday, November 13, 2025, at 10:00 a.m. ET.
• Jefferies 2025 London Healthcare Conference with a fireside chat on Thursday, November 20, 2025, at 10:00 a.m. GMT/ 5:00 a.m. ET.

A live webcast of the fireside chats will be available in the Investor section of the Company's website at www.syndax.com, where a replay will also be available for a limited time.

About Syndax

Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj^® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X and LinkedIn.

Syndax Contacts
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827

SNDX-G

FAQ

When will Syndax (SNDX) present at the UBS Global Healthcare Conference in 2025?

Syndax will present at the UBS Global Healthcare Conference on November 10, 2025 at 11:00 a.m. ET.

How can investors watch Syndax (SNDX) fireside chats in November 2025?

A live webcast and a limited-time replay will be available in the Investor section at www.syndax.com.

What time is Syndax (SNDX) scheduled to speak at the Jefferies London Healthcare Conference?

Syndax is scheduled for November 20, 2025 at 10:00 a.m. GMT (5:00 a.m. ET).

Which Syndax executive will participate in the November 2025 investor conferences?

Chief Executive Officer Michael A. Metzger and other members of Syndax management will participate.

Is there a replay available after Syndax (SNDX) conference presentations in November 2025?

Yes. A replay will be available for a limited time on the company's Investor website at www.syndax.com.